EUVIMEDEUVIMED entdecken
Crossref

Fc Multisite Conjugation and Prolonged Delivery of the Folate-Targeted Drug Conjugate EC140

Yan Zheng, Hong Cheng, Sibo Jiang, Wanyi Tai iD

Bioconjugate Chemistry · 16.04.2025 · 36 (4) · 762-769

DOI: 10.1021/acs.bioconjchem.5c00037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 03.04.2025. Verfasst von Yan Zheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China. Hauptthemen laut MEDLINE: Folic Acid, Immunoglobulin Fc Fragments, Immunoconjugates, Drug Delivery Systems. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: the National Key R&D Program of China, the Postdoctoral Fellowship Program of CPSF, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecule-drug conjugate (SMDC) is a targeted drug delivery technology that develops in parallel with the antibody-drug conjugate. However, the clinical translation of SMDC faces challenges due to its limited circulating half-life in vivo. The drawback in pharmacokinetics is that it restricts the exposure time of SMDC to tumor tissues and ultimately reduces the therapeutic efficacy. In this study, we chemically conjugated a folate-targeted SMDC EC140 to the long-circulating Fc protein at multiple sites, yielding a stable and high-DAR Fc-SMDC conjugate (Fc-EC140). Fc-EC140 can bear approximately 4 molecules of EC140 per Fc protein (drug-antibody ratio = 4.1) and display enhanced potency in folate receptor (FR)-positive tumor cells compared to the SMDC comparator. In addition, Fc-EC140 retains the FcRn-mediated recycling function and displays an extended half-life of 28 h in the mice. In vivo, antitumor experiments demonstrate that intravenous administration of Fc-EC140 (Q7D × 3 at a dose of 15 mg/kg) nearly cures the KB tumors, which is far more effective than the comparator EC140 administrated at equivalent doses. This study presents a new strategy for the targeted delivery of SMDC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Folic AcidImmunoglobulin Fc FragmentsImmunoconjugatesDrug Delivery SystemsAntineoplastic AgentsAnimalsHumansMiceReceptors, FcCell Line, TumorFemale

Substanzen

Folic AcidImmunoglobulin Fc FragmentsImmunoconjugatesReceptors, FcAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
  • Department of Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei 430071, China.
  • Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, Hunan 410219, China.

ORCID-Profile: Wanyi Tai

Förderung

  • the National Key R&D Program of China
  • the Postdoctoral Fellowship Program of CPSF
  • the National Natural Science Foundation of China

Zitieren

APA

Zheng, Y., Cheng, H., Jiang, S., & Tai, W. (2025). Fc Multisite Conjugation and Prolonged Delivery of the Folate-Targeted Drug Conjugate EC140. Bioconjugate Chemistry, 36(4), 762-769. https://doi.org/10.1021/acs.bioconjchem.5c00037

Vancouver

Zheng Y, Cheng H, Jiang S, Tai W. Fc Multisite Conjugation and Prolonged Delivery of the Folate-Targeted Drug Conjugate EC140. Bioconjugate Chemistry. 2025;36(4):762-769. doi:10.1021/acs.bioconjchem.5c00037

BibTeX
@article{Zheng2025,
  author = {Zheng, Yan and Cheng, Hong and Jiang, Sibo and Tai, Wanyi},
  title = {Fc Multisite Conjugation and Prolonged Delivery of the Folate-Targeted Drug Conjugate EC140},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  volume = {36},
  number = {4},
  pages = {762--769},
  doi = {10.1021/acs.bioconjchem.5c00037}
}
Kostenlos starten →